This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Adam Feuerstein

Senior Columnist

Before joining TheStreet in March 2001, Feuerstein covered business software for Upside.com. Prior to that he covered a variety of business beats, including technology and commercial real estate, at the San Francisco Business Times.


Feuerstein graduated from Emory University with a bachelor's degree in political science.


Adam Feuerstein
By This Author:
Page 3 of 573

Sunesis Drug for Elderly Blood Cancer Patients Fails Phase III Study

By Adam Feuerstein

Sunesis' experimental drug vosaroxin did not extend survival of elderly patients with advanced acute myeloid leukemia compared to a placebo.

07:00AM 10/06/14

Biotech Stock Mailbag: Seattle Genetics, Achillion, Catalyst Pharma

By Adam Feuerstein

Biotech columnist Adam Feuerstein answers readers' questions about health care.

09:41AM 10/03/14

Why You Should Stay Away From the Ebola Frenzy in Biotech Stocks

By Adam Feuerstein

Ebola lands in Texas, so expect some crazy volatility Wednesday in biotech and drug stocks.

10:08AM 10/01/14

Shkreli's Inability to Focus, Immaturity Cost Him Retrophin CEO Job

By Adam Feuerstein

Martin is super smart and will be a great asset somewhere, but he is not a CEO. I wish him the best.

05:53PM 09/30/14

Why J&J Expands Antiviral Franchise but Doesn't Buy Achillion, Novavax

By Adam Feuerstein

What are the motivations behind significant takeovers, like J&J's takeover of Alios Biopharma? And why have companies like Achillion and Novavax been passed over?

09:49AM 09/30/14

Catalyst Pharma Closer to Unconscionable Price Hike for Rare-Disease Drug

By Adam Feuerstein

For the zero work done by Catalyst, LEMS patients will pay as much as $80,000 for the exact same drug they use now for a fraction of the cost.

07:20AM 09/30/14

Clovis Shares Higher on Improved Outlook for Lung Cancer Drug

By Adam Feuerstein

Clovis Oncology shares are higher Monday because AstraZeneca, its direct competitor to develop a new, genetically targeted lung cancer drug, slipped this weekend.

12:17PM 09/29/14

Seattle Genetics Seeks Expanded Use of Lymphoma Drug on Study Win

By Adam Feuerstein

Adcetris delayed disease progression in Hodgkin lymphoma patients following a stem cell transplant.

09:31AM 09/29/14

Biotech Stock Mailbag: ProQR, Vertex Pharma, Tekmira, Agios

By Adam Feuerstein

Biotech columnist Adam Feuerstein answers readers' questions about health care.

07:00AM 09/26/14

Gilead Sciences' Next-Generation HIV Drug Hits the Mark

By Adam Feuerstein

TAF is an improved version of Gilead's stalwart but patent challenged HIV drug Viread.

10:30AM 09/24/14

Page 3 of 573

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
DOW 16,677.90 +216.58 1.32%
S&P 500 1,950.82 +23.71 1.23%
NASDAQ 4,452.7920 +69.9450 1.60%

Brokerage Partners

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs